演題詳細

一般口演 / Oral Session

一般口演 99 (Oral Session 99) :ATL:臨床・病理

print

日程
2013年10月13日(日)
時間
16:00 - 17:00
会場
第7会場 / Room No.7 (ロイトン札幌 2F リージェント)
座長・司会
宇都宮 與 (Atae Utsunomiya):1
1:今村病院分院 血液内科
 
前へ戻る

Clinical significance of indoleamine 2,3-dioxygenase (IDO) expression in ATL

演題番号 : OS-3-143

正木 彩子 (Ayako Masaki):1、石田 高司 (Takashi Ishida):1、前田 康博 (Yasuhiro Maeda):2、稲垣 淳 (Atsushi Inagaki):3、鈴木 進 (Susumu Suzuki):4、伊藤 旭 (Asahi Ito):1、森 芙美子 (Fumiko Mori):1、佐藤 文彦 (Fumihiko Sato):5、成田 朋子 (Tomoko Narita):1、李 政樹 (Masaki Ri):1、楠本 茂 (Shigeru Kusumoto):1、小松 弘和 (Hirokazu Komatsu):1、新実 彰男 (Akio Niimi):1、上田 龍三 (Ryuzo Ueda):4、稲垣 宏 (Hiroshi Inagaki):5、宇都宮 與 (Atae Utsunomiya):6、飯田 真介 (Shinsuke Iida):1

1:Dept. Medical Oncology & Immunology, Nagoya City University, Nagoya Japan、2:Dept. Hospital Pharmacy, Nagoya City University, Nagoya, Japan、3:Dept. Hematology and Oncology, Nagoya City West Medical Center, Nagoya, Japan、4:Dept. Tumor Immunology, Aichi Medical University, Nagakute, Japan、5:Pathology and Core Laboratory, Nagoya City University, Nagoya, Japan、6:Dept. Hematology, Imamura Bun-in Hospital, Kagoshima, Japan

 

Purpose: The interactions between tumor and host cells create an immunosuppressive network protecting the tumor from immune attack. We examined the contribution of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in ATL.Experimental Design: Activity of IDO was assessed by HPLC in sera from 96 ATL patients, 36 HTLV-1 asymptomatic carriers (AC), and 40 healthy volunteers who provided written informed consent for participation. Immunohistochemistry was used to evaluate IDO expression in tissue samples from ATL patients.Results: The serum kynurenine/tryptophan ratio indicating IDO activity was significantly higher in the HTLV-1 AC (median, 9.29; range, 4.50-18.73) compared to healthy volunteers (5.98; 3.57-9.66) (P<0.001), but was significantly higher in the ATL patients (12.75; 3.71-75.50) than in HTLV-1 AC (P<0.001). Multivariate analysis including 8 variables, which were age, IDO activity, clinical variant, gender, PS, serum sIL2R concentration, serum Alb level, and blood eosinophil counts, demonstrated that the following 3 variables significantly contributed to poorer overall survival: older age (>71 years, HR 2.238; 95% CI, 1.148-4.365), IDO activity (>15.3, 2.042; 1.070-3.900), and worse PS (2-4, 1.865; 1.032-3.370). Immunohistochemical analysis demonstrated that IDO was mainly produced by ATL cells.Conclusion: The present study indicated that IDO expression was involved in the progression of HTLV-1 infected cells and significantly correlated with unfavorable outcome in ATL patients. The establishment of a novel treatment strategy targeting IDO is warranted.

前へ戻る